Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories'
Quetiapine Fumarate 300 mg Tablet under fasted steady state conditions.